• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞毒性T淋巴细胞浸润和趋化因子可独立于三阴性乳腺癌的肿瘤突变负荷预测患者的长期生存。

Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer.

作者信息

Katsuta Eriko, Yan Li, Opyrchal Mateusz, Kalinski Pawel, Takabe Kazuaki

机构信息

Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

出版信息

Ther Adv Med Oncol. 2021 Apr 5;13:17588359211006680. doi: 10.1177/17588359211006680. eCollection 2021.

DOI:10.1177/17588359211006680
PMID:33868461
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8024454/
Abstract

BACKGROUND

Cytotoxic T-lymphocyte (CTL) infiltration into tumor is a positive prognostic factor in breast cancer. High tumor mutational burden (TMB) is also considered as a predictor of tumor immunogenicity and response to immunotherapy. However, it is unclear whether the infiltration of functional CTL simply reflects the TMB or represents an independent prognostic value.

METHODS

Utilizing The Cancer Genome Atlas (TCGA) breast cancer cohort, we established the Functional Hotness Score (FHS). The associations of FHS and breast cancer patient prognosis as well as distinct immunity markers were analyzed in a total of 3011 breast cancer patients using TCGA, METABRIC and metastatic breast cancer (MBC) cohort GSE110590.

RESULTS

We established FHS, based on , and gene expression levels of bulk tumors, which delivered the best prognostic value among some gene combinations. Breast cancer patients with the high-FHS tumors showed significantly better survival. FHS was lower in the MBCs. Triple-negative breast cancer (TNBC) showed the highest FHS among subtypes. FHS predicted patient survival in hormone receptor (HR)-negative, especially in TNBC, but not in HR-positive breast cancer. FHS predicted patient prognosis independently in TNBC. The high-FHS TNBCs showed not only higher CD8+ T cell infiltration, but also enhanced broader type-1 anti-cancer immunity. The patients with the high-FHS tumors showed better prognosis not only in high-TMB tumors but also in low-TMB TNBCs. The combination of high-TMB with high-FHS identified a unique subset of patients who do not recur over time in TNBC.

CONCLUSION

TNBCs with high FHS based on the expression levels of , and showed improved prognosis with enhanced anti-cancer immunity regardless of TMB. FHS constitutes an independent prognostic marker of survival, particularly robustly when combined with TMB in TNBC.

摘要

背景

细胞毒性T淋巴细胞(CTL)浸润肿瘤是乳腺癌的一个阳性预后因素。高肿瘤突变负荷(TMB)也被视为肿瘤免疫原性和免疫治疗反应的一个预测指标。然而,尚不清楚功能性CTL的浸润是仅仅反映了TMB,还是代表着一种独立的预后价值。

方法

利用癌症基因组图谱(TCGA)乳腺癌队列,我们建立了功能热点评分(FHS)。使用TCGA、METABRIC和转移性乳腺癌(MBC)队列GSE110590,在总共3011例乳腺癌患者中分析了FHS与乳腺癌患者预后以及不同免疫标志物之间的关联。

结果

我们基于实体瘤的 、 和 基因表达水平建立了FHS,在一些基因组合中,它具有最佳的预后价值。FHS高的肿瘤的乳腺癌患者显示出明显更好的生存率。MBC中的FHS较低。三阴性乳腺癌(TNBC)在各亚型中FHS最高。FHS可预测激素受体(HR)阴性患者的生存情况,尤其是TNBC患者,但不能预测HR阳性乳腺癌患者的生存情况。在TNBC中,FHS可独立预测患者预后。FHS高的TNBC不仅显示出更高的CD8 + T细胞浸润,还增强了更广泛的1型抗癌免疫。FHS高的肿瘤患者不仅在高TMB肿瘤中,而且在低TMB的TNBC中都显示出更好的预后。高TMB与高FHS的组合确定了TNBC中一组随时间不复发的独特患者亚群。

结论

基于 、 和 表达水平的FHS高的TNBC显示出抗癌免疫力增强,预后改善,且与TMB无关。FHS构成生存的独立预后标志物,在TNBC中与TMB联合时尤其有力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/9b02b3fb49dd/10.1177_17588359211006680-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/7a08366b13f1/10.1177_17588359211006680-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/3329ab97765d/10.1177_17588359211006680-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/d0e3cbb88075/10.1177_17588359211006680-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/44b9ed15f78b/10.1177_17588359211006680-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/1f24cf0e26e9/10.1177_17588359211006680-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/862bd49b66b3/10.1177_17588359211006680-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/9b02b3fb49dd/10.1177_17588359211006680-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/7a08366b13f1/10.1177_17588359211006680-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/3329ab97765d/10.1177_17588359211006680-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/d0e3cbb88075/10.1177_17588359211006680-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/44b9ed15f78b/10.1177_17588359211006680-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/1f24cf0e26e9/10.1177_17588359211006680-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/862bd49b66b3/10.1177_17588359211006680-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b4c/8024454/9b02b3fb49dd/10.1177_17588359211006680-fig7.jpg

相似文献

1
Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer.细胞毒性T淋巴细胞浸润和趋化因子可独立于三阴性乳腺癌的肿瘤突变负荷预测患者的长期生存。
Ther Adv Med Oncol. 2021 Apr 5;13:17588359211006680. doi: 10.1177/17588359211006680. eCollection 2021.
2
Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.三阴性乳腺癌的肿瘤突变负担和免疫浸润特征:全基因组高通量数据分析。
Front Immunol. 2021 Apr 21;12:650491. doi: 10.3389/fimmu.2021.650491. eCollection 2021.
3
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.三阴性乳腺癌中基因组指标与免疫浸润的相关性研究。
JAMA Oncol. 2017 Dec 1;3(12):1707-1711. doi: 10.1001/jamaoncol.2017.2140.
4
Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in -Aberrant Triple-Negative Breast Cancer.硫酸软骨素蛋白聚糖4(CSPG4)和程序性死亡受体1(PDL1)在异常三阴性乳腺癌中的共表达及联合预后价值
Front Oncol. 2022 Feb 24;12:804466. doi: 10.3389/fonc.2022.804466. eCollection 2022.
5
The potent potential of MFAP2 in prognosis and immunotherapy of triple-negative breast cancer.MFAP2在三阴性乳腺癌预后及免疫治疗中的强大潜力。
Discov Oncol. 2024 Jun 1;15(1):202. doi: 10.1007/s12672-024-01044-7.
6
Correlation Between Immune Cell Infiltration and PD-L1 Expression and Immune-Related lncRNA Determination in Triple-Negative Breast Cancer.三阴性乳腺癌中免疫细胞浸润与PD-L1表达及免疫相关lncRNA测定的相关性
Front Genet. 2022 Mar 31;13:878658. doi: 10.3389/fgene.2022.878658. eCollection 2022.
7
ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.通过对肿瘤突变负担和免疫浸润的联合分析,ADRB1 被确定为乳腺癌的一个潜在生物标志物。
Aging (Albany NY). 2020 Nov 21;13(1):351-363. doi: 10.18632/aging.104204.
8
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.肿瘤突变负荷是乳腺癌免疫介导生存的一个决定因素。
Oncoimmunology. 2018 Jul 30;7(10):e1490854. doi: 10.1080/2162402X.2018.1490854. eCollection 2018.
9
Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.基于肿瘤突变负荷分析的胃癌基因预后模型的鉴定。
Pathol Oncol Res. 2021 Sep 10;27:1609852. doi: 10.3389/pore.2021.1609852. eCollection 2021.
10
Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.头颈部癌中的肿瘤突变负担、免疫细胞浸润和免疫相关基因预后模型的构建。
Int J Med Sci. 2021 Jan 1;18(1):226-238. doi: 10.7150/ijms.51064. eCollection 2021.

引用本文的文献

1
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer.三阴性乳腺癌患者的系统性趋化因子调节方案联合新辅助化疗。
J Immunother Cancer. 2024 Nov 14;12(11):e010058. doi: 10.1136/jitc-2024-010058.
2
The Potential of Immunotherapy for SMARCA4-Deficient Undifferentiated Uterine Sarcoma (SDUS).免疫疗法治疗 SMARCA4 缺陷型未分化子宫肉瘤(SDUS)的潜力。
Biomolecules. 2024 Aug 11;14(8):987. doi: 10.3390/biom14080987.
3
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs.

本文引用的文献

1
The association between tumor mutational burden and prognosis is dependent on treatment context.肿瘤突变负担与预后的关联取决于治疗背景。
Nat Genet. 2021 Jan;53(1):11-15. doi: 10.1038/s41588-020-00752-4. Epub 2021 Jan 4.
2
Clinical relevance of tumor microenvironment: immune cells, vessels, and mouse models.肿瘤微环境的临床相关性:免疫细胞、血管和小鼠模型。
Hum Cell. 2020 Oct;33(4):930-937. doi: 10.1007/s13577-020-00380-4. Epub 2020 Jun 7.
3
Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
自然杀伤细胞受体信号降低 TCR 激活阈值,增强 TAA 特异性 CTL 对癌细胞的选择性识别。
Cancer Immunol Res. 2024 Oct 1;12(10):1421-1437. doi: 10.1158/2326-6066.CIR-24-0061.
4
Increased PIEZO1 Expression Is Associated with Worse Clinical Outcomes in Hormone-Receptor-Negative Breast Cancer Patients.PIEZO1表达增加与激素受体阴性乳腺癌患者较差的临床结局相关。
Cancers (Basel). 2024 Feb 6;16(4):683. doi: 10.3390/cancers16040683.
5
NK Receptors Replace CD28 As the Dominant Source of Signal 2 for Cognate Recognition of Cancer Cells by TAA-specific Effector CD8 T Cells.NK受体取代CD28成为TAA特异性效应CD8 T细胞对癌细胞进行同源识别时信号2的主要来源。
Res Sq. 2023 Oct 19:rs.3.rs-3399211. doi: 10.21203/rs.3.rs-3399211/v1.
6
Distinct immune microenvironment of lung adenocarcinoma in never-smokers from smokers.不吸烟与吸烟肺腺癌患者的独特免疫微环境。
Cell Rep Med. 2023 Jun 20;4(6):101078. doi: 10.1016/j.xcrm.2023.101078. Epub 2023 Jun 9.
7
Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance.基于免疫组织化学的三阴性乳腺癌分子分型及其预后意义。
Pathol Oncol Res. 2023 May 19;29:1611162. doi: 10.3389/pore.2023.1611162. eCollection 2023.
8
Development and validation of prognostic index based on immunogenic cell death-related genes with melanoma.基于免疫原性细胞死亡相关基因的黑色素瘤预后指数的开发与验证
Front Oncol. 2022 Nov 7;12:1011046. doi: 10.3389/fonc.2022.1011046. eCollection 2022.
9
Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy.三阴性乳腺癌分子亚型中与免疫原性细胞死亡相关的损伤相关分子模式和传感受体及其对免疫治疗的意义
Front Oncol. 2022 Apr 4;12:870914. doi: 10.3389/fonc.2022.870914. eCollection 2022.
10
APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival.载脂蛋白B mRNA编辑酶催化多肽样3F(APOBEC3F)在三阴性乳腺癌中的表达与肿瘤微环境浸润、癌症免疫激活及生存期改善相关。
Am J Cancer Res. 2022 Feb 15;12(2):744-762. eCollection 2022.
胃腺癌中 PD-L1 联合肿瘤浸润淋巴细胞、EB 病毒和微卫星不稳定性的预后预测。
Diagn Pathol. 2020 Jun 4;15(1):69. doi: 10.1186/s13000-020-00979-z.
4
Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma.成纤维细胞作为胰腺导管腺癌根治性切除的生物学标志物。
Int J Mol Sci. 2020 May 29;21(11):3890. doi: 10.3390/ijms21113890.
5
High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer.在三阴性乳腺癌中,高 MYC mRNA 表达比 MYC DNA 扩增更具临床相关性。
Int J Mol Sci. 2019 Dec 28;21(1):217. doi: 10.3390/ijms21010217.
6
Current status and limitations of immunotherapy for breast cancer.乳腺癌免疫治疗的现状与局限性
Surgery. 2020 Mar;167(3):628-630. doi: 10.1016/j.surg.2019.09.018. Epub 2019 Oct 14.
7
High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptor‑positive breast cancer.骨形态发生蛋白(BMP)6和BMP7的高表达与雌激素受体阳性乳腺癌中更高的免疫细胞浸润及更好的生存率相关。
Oncol Rep. 2019 Oct;42(4):1413-1421. doi: 10.3892/or.2019.7275. Epub 2019 Aug 12.
8
PD-1 Expression and Function of T-Cell Subsets in TILs From Human Lung Cancer.PD-1 在人肺癌 TILs 中 T 细胞亚群的表达和功能。
J Immunother. 2019 Oct;42(8):297-308. doi: 10.1097/CJI.0000000000000292.
9
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?血浆中程序性死亡蛋白1(PD-1)水平能否预测转移性黑色素瘤患者肿瘤浸润淋巴细胞的存在及效能?
Ther Adv Med Oncol. 2019 May 13;11:1758835919848872. doi: 10.1177/1758835919848872. eCollection 2019.
10
Recent advances in triple negative breast cancer: the immunotherapy era.三阴性乳腺癌的最新进展:免疫治疗时代。
BMC Med. 2019 May 9;17(1):90. doi: 10.1186/s12916-019-1326-5.